Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Cervical cancer, drawn from the whole corpus: 120 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
4 medicines on record are linked to one of the types below rather than to Cervical cancer itself. Grouped by the type that holds them; each list opens that type's own page.
Vaccine and screening access in LMICs.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Brachytherapy capacity.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Delivery, not discovery: the disease is preventable, yet global HPV vaccination coverage of girls is around 27% and 350,000 women still die of it each year.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Screening reaches under 30% of women in most low- and middle-income countries; brachytherapy capacity is absent in much of Africa.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Pembrolizumab with chemoradiation costs far more than induction chemotherapy; how to combine or choose between KEYNOTE-A18 and INTERLACE is untested.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Recurrent disease after chemo-immunotherapy has few options; tisotumab adds two months of median survival.
Also on OnCo: Treatment journeys · Survivorship planner.
HPV-independent (gastric-type) adenocarcinoma and neuroendocrine carcinoma have poor outcomes and no specific therapy.
Minimally invasive surgery's harm mechanism is unresolved; protective-technique trials (RACC, ROCC) are pending.
Therapeutic HPV vaccines (E6/E7-directed) have repeatedly shown immunogenicity without clear clinical benefit in invasive cancer.
Fertility preservation options for tumours over 2 cm remain limited.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 50 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Recurrent/metastatic cervical after systemic therapy; 28 Mar 2025
A milestone in how this cancer is treated.
First-line cervical cancer (COMPASSION-16)
First-line persistent/recurrent/metastatic cervical cancer with chemotherapy ± bevacizumab; first-line gastric cancer with chemotherapy